Newron Pharmaceuticals SpA (CH:NWRN)
:NWRN
Top Page
Newron Pharmaceuticals SpA
(NWRN)
Select Model
Select Model
Rating:50Neutral
Price Target:
CHF14.50
▼(-2.16% Downside)
Action:ReiteratedDate:03/26/26
The score is held back mainly by weak/volatile financial performance (sharp 2025 revenue decline, losses, and a highly leveraged balance sheet with negative equity) and bearish technicals. Offsetting this, the latest earnings call conveyed strong clinical/program momentum and improved liquidity runway via the Eisai deal and deferred debt service, which meaningfully supports the outlook despite execution and conditional-funding risks.
Positive Factors
Strategic partnership & funding
The Eisai licensing deal delivered EUR 48m and access to further non-dilutive financing while EIB repayments were deferred to 2028. That materially extends runway to complete pivotal readouts, reduces immediate refinancing pressure and lets management prioritize execution and regulatory milestones.
Negative Factors
Weak balance sheet / negative equity
Negative equity and substantial debt create structural financial fragility. High leverage limits strategic flexibility, increases refinancing and dilution risk, and can force expensive or dilutive financing choices that impair the company's ability to invest in R&D and execute long-term commercial plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic partnership & funding
The Eisai licensing deal delivered EUR 48m and access to further non-dilutive financing while EIB repayments were deferred to 2028. That materially extends runway to complete pivotal readouts, reduces immediate refinancing pressure and lets management prioritize execution and regulatory milestones.
Read all positive factors
Newron Pharmaceuticals SpA (NWRN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF308.17M
Dividend YieldN/A
Average Volume (3M)170.30K
Price to Earnings (P/E)―
Beta (1Y)1.90
Revenue Growth744.64%
EPS GrowthN/A
CountryCH
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.60
Shares Outstanding20,794,209
10 Day Avg. Volume255,106
30 Day Avg. Volume170,297
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)-45.95
Price to Sales (P/S)26.56
P/FCF Ratio15.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF47.60Price Target Upside221.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.18
Revenue Forecast (FY)CHF44.69M
Newron Pharmaceuticals SpA Business Overview & Revenue Model
Company Description
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers...
How the Company Makes Money
Newron primarily makes money through (1) partnering and licensing arrangements for its drug assets and (2) product-related income where applicable. A key component has been collaboration income tied to commercialization of its Parkinson’s disease-...
Newron Pharmaceuticals SpA Earnings Call Summary
Earnings Call Date:Mar 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Sep 22, 2026
Earnings Call Sentiment Positive
The call presented multiple strong positive developments: validation from a top-tier partner (Eisai) and EUR 48m collected, a large global pivotal program across >1,300 patients with significant Phase III/Phase II efficacy signals (8A: PANSS p=0.006; CGI-S p=0.037), an improved IP position (European crystalline patent and potential U.S. grant to extend exclusivity to 2044), robust safety/tolerability and clear commercial expansion potential. Management has secured non-dilutive runway and delayed debt service to mid-2028. Principal risks flagged were operational recruitment challenges, parts of funding conditional on positive results (EUR 12m), pending U.S. patent timing, and the fact that a NASDAQ uplisting is not currently achievable without further progress. On balance the highlights (clinical validation, funding, IP progress, safety, analyst coverage) substantially outweigh the lowlights, though the company remains dependent on upcoming pivotal readouts and execution.Positive Updates
Strategic Partnership and Initial Funding Secured
December 2024 licensing deal with EA (Eisai Group) validated evenamide and generated EUR 48 million collected to advance Phase III. New funding agreement provides access up to EUR 38 million (EUR 15m already in bank, EUR 11m expected before year-end with no milestones attached, and EUR 12m conditional on positive pivotal results). European Investment Bank loan repayments delayed to no earlier than June 2028, improving near-term liquidity runway.
Negative Updates
Reliance on Upcoming Pivotal Readouts and Conditional Funding
A material portion of near-term funding (EUR 12 million) is conditional on positive pivotal results by year-end; management excluded this conditional amount from cash guidance. Success timelines and some funding are therefore contingent on trial outcomes.
Read all updates
Q4-2025 Updates
Positive
Negative
Strategic Partnership and Initial Funding Secured
December 2024 licensing deal with EA (Eisai Group) validated evenamide and generated EUR 48 million collected to advance Phase III. New funding agreement provides access up to EUR 38 million (EUR 15m already in bank, EUR 11m expected before year-end with no milestones attached, and EUR 12m conditional on positive pivotal results). European Investment Bank loan repayments delayed to no earlier than June 2028, improving near-term liquidity runway.
Read all positive updates
Company Guidance
Guidance from the call was that Newron expects 12‑week pivotal readouts within 2026 and aims to complete enrollment in ENIGMA‑TRS‑1 (a 600‑patient, 52‑week TRS study with a 12‑week primary endpoint) by end‑August 2026 with primary results by year‑end and a likely NDA filing in Q1–Q2 2027; ENIGMA‑TRS‑2 (a shorter 12‑week pivotal) may report topline in Q4‑26/early‑Jan and announcements will be separate. Management said the company is running three pivotal studies (>1,300 patients worldwide), has the cash to reach the 12‑week readouts (EUR 48m received from the Eisai deal plus access to up to EUR 38m new financing: EUR 15m already in the bank, EUR 11m expected before year‑end, and EUR 12m conditional on positive pivotal results), and that a positive readout would likely unlock the conditional EUR 12m and extend runway into late‑2027 (an extra ~6–9 months per management). The European Investment Bank loan repayments were deferred to not before June 2028, shareholders will vote on April 23, 2026 on a 15% capital increase (and 5% for option plans) to support additional indications/uplisting, and Newron noted ~20.8m shares outstanding, ~1.6m warrants, daily turnover of ~0.7–1% of the stock and a pending crystalline‑form composition‑of‑matter patent that could extend exclusivity to 2044 (current US COM to 2035; process patents to 2042).Newron Pharmaceuticals SpA Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
18
Very Negative
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 19.25M | 51.39M | 9.06M | 6.09M | 5.76M |
| Gross Profit | 0.00 | 51.39M | 9.06M | 6.09M | 5.76M |
| EBITDA | -4.55M | 25.94M | -11.83M | -13.32M | -11.92M |
| Net Income | -13.33M | 15.84M | -16.22M | -17.49M | -14.90M |
Balance Sheet | |||||
| Total Assets | 40.02M | 63.91M | 25.87M | 37.20M | 50.49M |
| Cash, Cash Equivalents and Short-Term Investments | 28.85M | 9.83M | 12.60M | 22.77M | 34.59M |
| Total Debt | 38.13M | 50.47M | 48.41M | 45.66M | 43.08M |
| Total Liabilities | 51.15M | 62.45M | 55.77M | 51.23M | 47.38M |
| Stockholders Equity | -11.13M | 1.46M | -29.91M | -14.03M | 3.11M |
Cash Flow | |||||
| Free Cash Flow | 32.51M | -17.63M | -10.15M | -11.11M | -11.46M |
| Operating Cash Flow | 32.56M | -17.61M | -10.14M | -11.09M | -11.45M |
| Investing Cash Flow | -13.75M | 3.16M | 3.25M | -317.00K | 8.42M |
| Financing Cash Flow | -13.52M | 15.05M | -192.00K | -186.00K | 14.83M |
Newron Pharmaceuticals SpA Technical Analysis
Negative
14.82
Price Trends
18.73
Negative
19.27
Negative
14.27
Positive
Market Momentum
-1.28
Positive
31.31
Neutral
43.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:NWRN, the sentiment is Negative. The current price of 14.82 is below the 20-day moving average (MA) of 16.45, below the 50-day MA of 18.73, and above the 200-day MA of 14.27, indicating a neutral trend. The MACD of -1.28 indicates Positive momentum. The RSI at 31.31 is Neutral, neither overbought nor oversold. The STOCH value of 43.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:NWRN.
Newron Pharmaceuticals SpA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF640.82M | 16.63 | ― | ― | 58.51% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | CHF308.17M | -38.37 | ― | ― | 744.64% | ― | |
48 Neutral | CHF213.03M | -0.98 | -301.13% | ― | -56.85% | -186.55% | |
45 Neutral | CHF131.02M | -2.50 | -51.05% | ― | -100.00% | 14.45% | |
45 Neutral | CHF770.58M | -8.17 | ― | ― | 229.23% | 63.47% |
* Healthcare Sector Average
CH:NWRN
Newron Pharmaceuticals SpA
14.82
7.02
90.00%
CH:MOLN
Molecular Partners AG
3.25
-0.31
-8.85%
CH:BSLN
Basilea Pharmaceutica
52.60
7.40
16.37%
CH:IDIA
Idorsia Ltd
3.07
2.05
200.79%
CH:SANN
Santhera Pharmaceuticals Holding
15.18
0.04
0.26%
CH:XLS
Xlife Sciences Ltd.
20.50
-1.90
-8.48%
Newron Pharmaceuticals SpA Corporate Events
Newron bolsters finances as Evenamide enters pivotal global Phase III
Mar 24, 2026
Newron Pharmaceuticals reported a transformative 2025 marked by major advances in its Evenamide program, including regulatory approval and global initiation of the ENIGMA-TRS Phase III trials for treatment-resistant schizophrenia, expanded intelle...
Newron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul
Mar 24, 2026
Newron reported 2025 as a landmark year, driven by progress in its Evenamide program, including regulatory approval and initiation of the pivotal ENIGMA-TRS phase III trials in treatment-resistant schizophrenia across multiple regions. Partner EA ...
Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress
Mar 20, 2026
Newron Pharmaceuticals will showcase new data on its lead drug candidate Evenamide at the 2026 Schizophrenia International Research Society congress in Florence, highlighting glutamatergic modulation as a potential approach for treatment-resistant...
Newron extends EIB loan maturities to align financing with Evenamide milestones
Mar 19, 2026
Newron Pharmaceuticals has reached an agreement in principle with the European Investment Bank to extend the maturity of all outstanding tranches under its 2018 finance contract to 28 June 2028. The modification, which remains subject to definitiv...
Newron refreshes board with CNS and capital markets experts ahead of AGM
Mar 18, 2026
Newron Pharmaceuticals announced upcoming changes to its Board of Directors ahead of the 23 April 2026 Annual General Meeting, with long‑serving members Patrick Langlois and company founder and former CEO Luca Benatti not standing for reR...
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide
Feb 16, 2026
Newron Pharmaceuticals has secured commitments of up to EUR 38 million from a group of existing and new shareholders in Europe and Asia through a multi-tranche subscription of newly issued shares. The first tranche, worth up to EUR 15 million at E...
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug
Feb 16, 2026
Newron Pharmaceuticals has secured an equity financing package of up to EUR 38 million from existing and new investors in Europe and Asia, structured in three tranches of newly issued shares tied to the progress and outcome of its ENIGMA-TRS Phase...
Newron’s Evenamide Shows Durable Benefits as Add-On Therapy in Treatment-Resistant Schizophrenia
Feb 3, 2026
Newron Pharmaceuticals has highlighted a new peer-reviewed publication in Therapeutic Advances in Psychopharmacology reporting that its investigational drug Evenamide, a novel glutamate modulator, delivers clinically meaningful and durable benefit...
EA Pharma Starts Phase III Trial of Newron’s Evenamide for Treatment‑Resistant Schizophrenia in Japan
Jan 7, 2026
Newron Pharmaceuticals’ partner EA Pharma, a subsidiary of Eisai, has initiated a multicenter, randomized, double-blind, placebo-controlled Phase III trial in Japan of evenamide (EA8001) as an add-on therapy for patients with treatment-resis...
Newron Secures EU Patent Extension for Lead Schizophrenia Drug Evenamide
Jan 6, 2026
Newron Pharmaceuticals has secured a new European compound patent, EP4615820, covering the crystalline forms, manufacturing processes and uses of its lead schizophrenia drug candidate Evenamide, extending intended product exclusivity in the EU to ...
Newron Wins Long-Term EU Patent Protection for Lead Schizophrenia Drug Evenamide
Jan 6, 2026
Newron Pharmaceuticals has secured a new European compound patent (EP4615820) covering the crystalline forms, manufacturing processes and uses of its lead product candidate Evenamide, with protection expected to run until 2044. The patent grant, w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.